Claims for Patent: 8,926,979

Summary for Patent: 8,926,979

Title:	Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
Abstract:	Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc.gamma.RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc.gamma.RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan.RTM.), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan.RTM.), are also provided. The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-CD20 antibodies.
Inventor(s):	Aukerman; Sharon Lea (Moraga, CA), Luqman; Mohammad (Danville, CA)
Assignee:	Novartis AG (Basel, CH) XOMA Technology Ltd. (Berkeley, CA)
Application Number:	12/092,247
Patent Claims:	1. A method for treating a human patient for a cancer or pre-malignant condition that is associated with cells expressing both CD40 and CD20 and which is refractory to treatment with rituximab (Rituxan.RTM.), said method comprising: a) genotyping a biological sample obtained from said human patient to determine said human patient's Fc.gamma.RIIIa-158 genotype (V/V, V/F, or F/F); b) identifying said human patient as being heterozygous or homozygous for Fc.gamma.RIIIa-158F (genotype V/F or F/F), and c) administering to said human patient identified as being heterozygous or homozygous for Fc.gamma.RIIIa-158F (genotype V/F or F/F) a therapeutically or prophylactically effective amount of an anti-CD40 antibody that mediates antibody-dependent cellular cytotoxicity (ADCC) against CD40-expressing cells, wherein said treating results in at least one positive therapeutic response in said patient with respect to said cancer or pre-malignant condition. 2. A method according to claim 1, wherein said cancer or pre-malignant condition is a cancer of B-cell lineage. 3. A method according to claim 2, wherein said cancer of B-cell lineage is selected from the group consisting of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), small lymphocytic leukemia (SLL), hairy cell leukemia, Hodgkin's disease, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and lymphomas. 4. A method according to claim 1, wherein said cancer or pre-malignant condition is a non-B cell hematological malignancy. 5. A method according to claim 4, wherein said non-B cell hematological malignancy is acute myelocytic leukemia. 6. A method according to claim 1, wherein said cancer or pre-malignant condition is a solid tumor. 7. A method according to claim 6, wherein the solid tumor is selected from the group consisting of ovarian, lung, breast, colon, kidney, bladder, liver, gastric, cervical, prostate, nasopharyngeal, thyroid, and skin cancers, and sarcomas. 8. A method according to claim 1, wherein said anti-CD40 antibody is administered by a parenteral route of administration. 9. A method according to claim 8, wherein said anti-CD40 antibody is administered intravenously or subcutaneously. 10. A method according to claim 1, wherein said anti-CD40 antibody is a human monoclonal antibody. 11. A method according to claim 10, wherein said human anti-CD40 monoclonal antibody comprises a human IgG1 heavy chain constant region. 12. A method according to claim 11, wherein said human anti-CD40 monoclonal antibody comprises the amino acid sequence recited in SEQ ID NO:4 or SEQ ID NO:5. 13. A method according to claim 1, wherein said anti-CD40 antibody is free of significant agonist activity. 14. A method according to claim 1, wherein said anti-CD40 antibody is an antagonist of CD40-CD40L signaling on CD40-expressing cells. 15. A method according to claim 1, wherein said anti-CD40 antibody is more potent than rituximab (Rituxan.RTM.) in an assay of antibody-dependent cellular cytotoxicity (ADCC), wherein the assay comprises incubating CD40-expressing cells and CD20-expressing cells with isolated human natural killer (NK) cells in the presence of the relevant antibody. 16. A method according to claim 1, wherein said anti-CD40 antibody is more potent than rituximab (Rituxan.RTM.) in a nude mouse xenograft tumor model. 17. A method according to claim 16, wherein said nude mouse xenograft tumor model uses the Daudi human lymphoma cell line of a myeloma cell line. 18. A method according to claim 1, wherein said anti-CD40 antibody binds to human CD40 with an affinity (K.sub.D) of at least about 10.sup.-6 M to at least about 10.sup.-12 M. 19. A method according to claim 1, wherein said anti-CD40 antibody binds to human Fc.gamma.RIIIa-158V with an affinity (K.sub.D) of at least about 0.5 .mu.M. 20. A method according to claim 1, wherein said anti-CD40 antibody binds to human Fc.gamma.RIIIa-158F with an affinity (K.sub.D) of at least about 12 .mu.M. 21. A method according to claim 1, wherein said anti-CD40 antibody binds to human Fc.gamma.RIIIa-158V with an affinity (K.sub.D) of at least about 0.5 .mu.M, and binds to human Fc.gamma.RIIIa-158F with an affinity (KD) of at least about 12 .mu.M. 22. The method of claim 1, wherein said anti-CD40 antibody is a monoclonal antibody comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NO:2; (b) SEQ ID NO:4; (c) SEQ ID NO:5; (d) SEQ ID NO:2 and SEQ ID NO:4; and (e) SEQ ID NO:2 and SEQ ID NO:5. 23. The method of claim 1, wherein said anti-CD40 antibody is selected from the group consisting of: (a) a monoclonal antibody comprising the variable and constant region sequences shown in SEQ ID NO:2; (b) a monoclonal antibody comprising the variable and constant region sequences shown in SEQ ID NO:4; (c) a monoclonal antibody comprising the variable and constant region sequences shown in SEQ ID NO:5; (d) a monoclonal antibody comprising the variable and constant region sequences shown in SEQ ID NO:2 and the variable and constant region sequences shown SEQ ID NO:4; and (e) a monoclonal antibody comprising the variable and constant region sequences shown in SEQ ID NO:2 and the variable and constant region sequences shown SEQ ID NO:5. 24. The method of claim 1, wherein said anti-CD40 antibody is the antibody CHIR-12.12 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5543. 25. The method of claim 1, wherein said anti-CD40 antibody comprises: (a) a light chain variable domain containing the complementarity determining region (CDR) residues of SEQ ID NO:2; and (b) a heavy chain variable domain containing the CDR residues of SEQ ID NO:4. 26. A method according to claim 3, wherein said lymphoma is selected from the group consisting of diffuse small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), mucosal associated lymphoid tissue lymphoma, monocytoid B cell lymphoma, splenic lymphoma, lymphomatoid granulomatosis, intravascular lymphomatosis, immunoblastic lymphoma, and AIDS-related lymphoma. 27. A method according to claim 7, wherein said lung cancer is a non-small cell lung cancer of the squamous cell carcinoma, adenocarcinoma, or large cell carcinoma type. 28. A method according to claim 7, wherein the said lung cancer is a small cell lung cancer. 29. A method according to claim 7, wherein said kidney cancer is renal cell carcinoma. 30. A method according to claim 7, wherein said liver cancer is hepatocellular carcinoma. 31. A method according to claim 7, wherein said thyroid cancer is thyroid papillary carcinoma. 32. A method according to claim 7, wherein said skin cancer is melanoma. 33. A method according to claim 6, wherein the solid tumor is a sarcoma. 34. A method according to claim 33, wherein said sarcoma is osteosarcoma or Ewing's sarcoma.

Details for Patent 8,926,979

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-11-01
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-11-01
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2025-11-01